Goto content

Leishrisk, Bridging Research and Leishmanianis Control

Leishrisk, Bridging Research and Leishmanianis Control

Kaladrug-R  contacts


| introduction | overview workpackages | Kaladrug-R SOPs | agenda | publications | contacts |


Coordination - Institute of Tropical Medicine Antwerp, Belgium

ITMA is specialised among others in (i) research on biomedical, clinical and operational aspects of tropical diseases and their control, and on the management of health care in developing countries and (ii) supporting and strengthening national and international authorities, organisations and institutions concerned with human health in developing countries. The mission of the department of Parasitology is to generate,disseminate and apply knowledge of human parasitic diseases as well as to strengthen the capacities tot his end in developing countries.
general coordinator: Prof. Dr. Jean-Claude Dujardin, Department of Parasitology (, )
clinical coordinator: Dr. Bart Ostyn, Department of Public Health (
lab coordinator: Manu Vanaerschot, Department of Parasitology (
administrator: Eva Mostmans, Department of Parasitology (



Partners (click on name for more info)
Strathclyde University
University of Antwerp
Universitaetsmedizin Charité
University of Tuebingen
Wellcome Trust Sanger Institute
Banaras Hindu University
B.P. Koirala Institute of Health Sciences
Institute of Pathology
Indian Institute Chemical Biology
Strathclyde University, Glasgow, UK.
The Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) was established in 2006 to create a world-class centre for research and teaching in drug discovery and development. Its formation brought together expertise in biology with complementary strengths in biomedicinal chemistry and pharmaceutical sciences. This has placed the University of Strathclyde in a strong position to exploit new developments in genome and proteome research for drug discovery in the 21st Century. The Antimicrobial Agents and Chemotherapy research group focuses on the development of pharmaceuticals for infectious diseases, understanding how existing drugs work, and the mechanisms and importance of drug resistance.
contact: Prof. Dr. Graham Coombs (
University of Antwerp, Antwerp, Belgium.
The UA Laboratory of Microbiology, Parasitology and Hygiene (LMPH) is active in the field of anti-oxidant and anti-infective drug discovery research and has developed state of art in vitro and in vivo laboratory models. Anti-oxidant research is focused on the measurements of the anti- and pro-oxidant activity of natural and synthesised compounds, using EPR and HPLC with coulometric detection. Anti-infective drug discovery research involves a multidisciplinary platform for the characterisation and further development of new synthetic and natural lead compounds against human tropical protozoa (with particular emphasis on Leishmania). Dedicated in vitro test systems, drug screening technologies and animal models are available to study parasite pathogenesis and drug interactions.
contact: Prof. Dr. Louis Maes (
Universitaetsmedizin Charité, Berlin, Germany.
The Department of Parasitology of the Institute of Microbiology and Hygiene deals with technologies for the molecular characterisation of fungi (C. albicans and dermatophytes) and parasitic protozoa (Leishmania spp.). Research is directed to the development of new approaches for diagnosis and epidemiology as well as to strategies for the treatment of diseases caused by these pathogens. One of the main interests is the detection of polymorphisms on DNA, RNA and protein levels to be used for epidemiological and population genetic studies of fungi and of protozoa.
contact: Prof. Dr.Gabrielle Schönian (
University of Tuebingen, Tuebingen, Germany.
The Department of Medical Biometry is experienced in modelling the transmission and control of infectious diseases and in data evaluation and parameter estimation. It has received funding from the European Union (Malaria Concerted Action, PncEURO, MODELREL, INFTRANS, SARScontrol), from the German Ministry of Health (smallpox prevention scenarios), the Bill Gates Foundation (modelling possible effects of malaria vaccines) and from Deutsche Forschungsgemeinschaft (vector-borne diseases, epidemiological models for onchocerciasis control).
contact: Prof. Dr. Martin Eichner (
Wellcome Trust Sanger Institute, Hinxton, UK.
The Wellcome Trust Sanger Institute is the leading genomics centre in Europe. It was the largest single contributor to the public human genome sequencing project, producing around one-third of the finished sequence. WTSI has also made major contributions to the sequencing of the C. elegans, mouse and zebrafish genomes. Over the last few years, WTSI has been increasing its activities in experimental and medical/population genetics, especially in human and mouse, although they also have active programs in the biology of enteric bacteria and malaria. WTSI has recently been awarded funding from the Wellcome Trust for the 5-years to 2011. As part of this funding process, WTSI has re-focussed its activities on natural and experimentally induced genetic variation in humans, model organisms and pathogens, relying on underlying strengths in high-throughput sequence and analysis and informatics. The Pathogen Sequencing Unit within WTSI comprises about 30 staff involved in analysis and annotation of sequences, and around 20 dedicated staff within the sequencing core. The PSU has published over 35 bacterial and eukaryotic genomes, including the agents of tuberculosis, leprosy, typhoid fever, plague, whooping cough, diphtheria, malaria, leishmaniasis, trypanosomiasis and many other important diseases. They have around 100 ongoing genome sequencing projects, ranging from viruses, through bacteria, protozoa and helminths. All of our sequence data is publicly available though our website.
contact: Dr. Matt Berriman (
Banaras Hindu University, Varanasi, India.
The Institute of Medical Sciences, Banaras Hindu University aims to serve the underdeveloped eastern region (Eastern UP, Bihar, MP) of India, with the research directed towards the problems encountered this geographical region. The infectious diseases unit is engaged in research in visceral leishmaniasis (VL) for the last 15 years. They have studied epidemiology, clinical behaviour, response to various therapeutic options, they have evolved new therapeutic modalities including the first oral drug miltefosine which was developed from the very beginning by this group from phase I to phase IV clinical trials. They described the large scale drug resistance in Indian VL, and reported novel mechanisms involved in it. They studied the cytokine response in VL both circulating as well as intra-lesional. They have developed clinical application of k39 rapid immunochromatographic test for diagnosis of VL.
contact: Prof. Dr. Shyam Sundar (
B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
The BPKIHS carries out health system research at primary, secondary and tertiary levels for overall community development in the eastern region of Nepal (composed of 16 districts). It has a special research interest in tropical and infectious diseases. BPKIHS has privileged links with the Sunsari, Morang and Dhankuta health districts covering a population of two million. The Tropical and Infectious Diseases Unit has been involved in kala-azar research since the last 9 years. The areas covered include validation of rapid diagnostic tests and efficacy of therapy including Miltefosine. The results of the above studies have helped to guide the national policies in the treatment and diagnosis of kala-azar. BPKIHS has been a partner in collaborative European Commission funded projects (KALANET and LEISHNATDRUG-R ICA4-2000-10109). A kala-azar diagnostic validation study on serological and urinary tests (TDR Project A30636) has been recently completed.
contact: Prof. Dr. Suman Rijal (
Institute of Pathology, New Delhi, India.
The Institute of Pathology is under the Indian Council of Medical Research (ICMR), Ministry of Health and Family Welfare, Govt. of India. The thrust areas for research in the Institute are Tumour Biology and Infectious Diseases. The Molecular Biology lab is involved in studying various aspects of Leishmania biology. The group is working on key issues in basic and clinical aspects of Leishmaniasis. They are involved in development of diagnostic assays for KA and PKDL and in identification of virulence and antimony resistance related genes in KA by genomic approaches. The DNA based diagnostic assay developed in the lab has been demonstrated to possess high sensitivity in clinical samples from KA and PKDL and led to a US patent. The test is now being used at referral centres in endemic areas.
contact: Prof. Dr. Poonam Salotra (
Indian Institute of Chemical Biology, Calcutta, India.
The Indian Institute of Chemical Biology (IICB) is one of the constituent laboratories of the Council of Scientific and Industrial Research (CSIR), New Delhi. The main emphasis of the laboratory is to conduct basic biomedical research with special emphasis on infectious diseases. Leishmania research at IICB has a long tradition. In recognition of IICB’s achievements and capabilities in this area, United Nations Development Project (UNDP) funded a major research program for conducting research work on the biology of Leishmania parasites during 1988-1996. The Leishmania research group at IICB is represented by several laboratories in which interaction is fostered at many levels.
contact: Prof. Dr. Syamal Roy (

Supporting projects